Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD)

Q: What does CUSIP 74065P101 represent in this 13F holders report?

CUSIP 74065P101 is the security identifier for PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in Q2 2023?

52 institutional investors reported PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share for Q2 2023. Use the holders table for investor-level position and value details.

CUSIP: 74065P101

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 65,427,364
Total 13F shares: 36,273,689
Share change: +7,039,441
Total reported value: $163,232,997
Put/Call ratio: 240%
Price per share: $4.50
Number of holders: 52
Value change: +$31,250,061
Number of buys: 40
Number of sells: 23

Quarterly Holders Quick Answers

What is CUSIP 74065P101?
CUSIP 74065P101 identifies PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 74065P101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BAKER BROS. ADVISORS LP	13F	Company	15%	10,123,824	$57,705,797	—	31 Mar 2023	13F
ORBIMED ADVISORS LLC	13F	Company	15%	10,039,691	$57,226,239	—	31 Mar 2023	13F
FMR LLC	13F	Company	6.9%	4,546,678	$25,916,064	—	31 Mar 2023	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	3.5%	2,273,894	$12,961,196	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	1.4%	916,014	$5,221,280	—	31 Mar 2023	13F
Boxer Capital, LLC	13F	Company	1.1%	699,047	$3,985,000	—	31 Mar 2023	13F
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	13F	Company	0.79%	514,548	$2,932,924	—	31 Mar 2023	13F
BlackRock Finance, Inc.	13F	Company	0.65%	423,028	$2,411,260	—	31 Mar 2023	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.43%	284,362	$1,622,000	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.22%	145,904	$831,652	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.22%	141,662	$807,474	—	31 Mar 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.21%	138,500	$789,000	—	31 Mar 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.21%	136,519	$778,000	—	31 Mar 2023	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.2%	129,680	$739,176	—	31 Mar 2023	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.14%	90,200	$514,140	—	31 Mar 2023	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.13%	84,667	$482,602	—	31 Mar 2023	13F
CITIGROUP INC	13F	Company	0.11%	70,767	$403,372	—	31 Mar 2023	13F
JANE STREET GROUP, LLC	13F	Company	0.1%	64,470	$367,479	—	31 Mar 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.1%	62,851	$358,251	—	31 Mar 2023	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.08%	50,500	$287,850	—	31 Mar 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.08%	49,496	$282,127	—	31 Mar 2023	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.07%	47,614	$271,000	—	31 Mar 2023	13F
D. E. Shaw & Co., Inc.	13F	Company	0.07%	47,249	$269,319	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	0.07%	43,889	$250,167	—	31 Mar 2023	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.06%	36,949	$210,609	—	31 Mar 2023	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.05%	34,298	$195,499	—	31 Mar 2023	13F
Qube Research & Technologies Ltd	13F	Company	0.05%	30,377	$173,149	—	31 Mar 2023	13F
683 Capital Management, LLC	13F	Company	0.04%	28,631	$163,197	—	31 Mar 2023	13F
TD ASSET MANAGEMENT INC	13F	Company	0.04%	28,440	$162,108	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.04%	28,186	$160,660	—	31 Mar 2023	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.03%	22,455	$127,994	—	31 Mar 2023	13F
HRT FINANCIAL LP	13F	Company	0.03%	22,175	$126,000	—	31 Mar 2023	13F
NORTHERN TRUST CORP	13F	Company	0.03%	21,167	$120,652	—	31 Mar 2023	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.02%	16,198	$92,329	—	31 Mar 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0.02%	13,352	$76,000	—	31 Mar 2023	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.02%	12,759	$72,726	—	31 Mar 2023	13F
Virtu Financial LLC	13F	Company	0.02%	11,201	$64,000	—	31 Mar 2023	13F
TWO SIGMA SECURITIES, LLC	13F	Company	0.02%	10,922	$62,255	—	31 Mar 2023	13F
BARCLAYS PLC	13F	Company	0.02%	10,322	$58,835	—	31 Mar 2023	13F
Cubist Systematic Strategies, LLC	13F	Company	0.01%	8,778	$50,035	—	31 Mar 2023	13F
DENALI ADVISORS LLC	13F	Company	0.01%	8,200	$46,740	—	31 Mar 2023	13F
ROYAL BANK OF CANADA	13F	Company	0.01%	5,258	$30,000	—	31 Mar 2023	13F
NISA INVESTMENT ADVISORS, LLC	13F	Company	0.01%	4,000	$23,000	—	31 Mar 2023	13F
Christopher Pierce	3/4/5	EVP and Chief of Business Oper	— mixed-class rows	211,546 mixed-class rows	$14,138	—	02 Sep 2021	3/4/5
Cutler Group LLC / CA	13F	Company	0%	2,130	$12,000	—	31 Mar 2023	13F
Middle East Fze Point72	13F	Individual	0%	1,680	$9,576	—	31 Mar 2023	13F
JPMORGAN CHASE & CO	13F	Company	0%	1,394	$8,000	—	31 Mar 2023	13F
Point72 Asset Management, L.P.	13F	Company	0%	1,222	$6,965	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0%	980	$5,586	—	31 Mar 2023	13F
China Universal Asset Management Co., Ltd.	13F	Company	0%	649	$3,699	—	31 Mar 2023	13F

Institutional Holders of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) as of Q2 2023

As of 30 Jun 2023, Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) was held by 52 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 36,273,689 shares. The largest 10 holders included ORBIMED ADVISORS LLC, BAKER BROS. ADVISORS LP, FMR LLC, Boxer Capital, LLC, EcoR1 Capital, LLC, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, BlackRock Inc., MASSACHUSETTS FINANCIAL SERVICES CO /MA/, and Woodline Partners LP. This page lists 52 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

-2

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.